WO2001057175A3 - Methods and materials relating to neurotrimin-like polypeptides and polynucleotides - Google Patents

Methods and materials relating to neurotrimin-like polypeptides and polynucleotides Download PDF

Info

Publication number
WO2001057175A3
WO2001057175A3 PCT/US2001/003651 US0103651W WO0157175A3 WO 2001057175 A3 WO2001057175 A3 WO 2001057175A3 US 0103651 W US0103651 W US 0103651W WO 0157175 A3 WO0157175 A3 WO 0157175A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polypeptides
neurotrimin
methods
materials relating
Prior art date
Application number
PCT/US2001/003651
Other languages
French (fr)
Other versions
WO2001057175A2 (en
Inventor
Bryan J Boyle
Nancy K Mize
Matthew C Arterburn
Y Tom Tang
George Yeung
Ping Zhou
Chenghua Liu
Vinod Asundi
Radoje T Drmanac
Meng-Yun Wang
Lichuan Chen
Yea-Huey Yang
Original Assignee
Hyseq Inc
Bryan J Boyle
Nancy K Mize
Matthew C Arterburn
Y Tom Tang
George Yeung
Ping Zhou
Chenghua Liu
Vinod Asundi
Radoje T Drmanac
Meng-Yun Wang
Lichuan Chen
Yea-Huey Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc, Bryan J Boyle, Nancy K Mize, Matthew C Arterburn, Y Tom Tang, George Yeung, Ping Zhou, Chenghua Liu, Vinod Asundi, Radoje T Drmanac, Meng-Yun Wang, Lichuan Chen, Yea-Huey Yang filed Critical Hyseq Inc
Priority to EP01908832A priority Critical patent/EP1409715A4/en
Priority to US10/311,823 priority patent/US20040116683A1/en
Priority to JP2001557993A priority patent/JP2004500082A/en
Priority to AU2001236658A priority patent/AU2001236658A1/en
Priority to CA002399644A priority patent/CA2399644A1/en
Publication of WO2001057175A2 publication Critical patent/WO2001057175A2/en
Publication of WO2001057175A3 publication Critical patent/WO2001057175A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted neurotrimin-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human thalamus (Hyseq clone identification number 10468562). Other aspects of the invention include vectors containing processes for producing novel human secreted neurotrimin-like polypeptides, and antibodies specific for such polypeptides.
PCT/US2001/003651 2000-02-03 2001-02-02 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides WO2001057175A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01908832A EP1409715A4 (en) 2000-02-03 2001-02-02 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides
US10/311,823 US20040116683A1 (en) 2001-02-02 2001-02-02 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides
JP2001557993A JP2004500082A (en) 2000-02-03 2001-02-02 Methods and materials for neurotrimine-like polypeptides and polynucleotides
AU2001236658A AU2001236658A1 (en) 2000-02-03 2001-02-02 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides
CA002399644A CA2399644A1 (en) 2000-02-03 2001-02-02 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US49691400A 2000-02-03 2000-02-03
US09/496,914 2000-02-03
US56087500A 2000-04-27 2000-04-27
US09/560,875 2000-04-27
US63208500A 2000-08-02 2000-08-02
US09/632,085 2000-08-02

Publications (2)

Publication Number Publication Date
WO2001057175A2 WO2001057175A2 (en) 2001-08-09
WO2001057175A3 true WO2001057175A3 (en) 2004-02-26

Family

ID=27414039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/003651 WO2001057175A2 (en) 2000-02-03 2001-02-02 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides

Country Status (5)

Country Link
EP (1) EP1409715A4 (en)
JP (1) JP2004500082A (en)
AU (1) AU2001236658A1 (en)
CA (1) CA2399644A1 (en)
WO (1) WO2001057175A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861283A (en) * 1995-03-31 1999-01-19 The University Of Medicine And Dentistry Of New Jersey DNA encoding a limbic system-associated membrane protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236589A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861283A (en) * 1995-03-31 1999-01-19 The University Of Medicine And Dentistry Of New Jersey DNA encoding a limbic system-associated membrane protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1409715A4 *

Also Published As

Publication number Publication date
CA2399644A1 (en) 2001-08-09
EP1409715A2 (en) 2004-04-21
JP2004500082A (en) 2004-01-08
WO2001057175A2 (en) 2001-08-09
EP1409715A4 (en) 2004-04-21
AU2001236658A1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
WO2001088092A3 (en) Methods and materials relating to stem cell factor-like (scf-like) polypeptides and polynucleotides
WO2001077169A3 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2001055336A3 (en) Methods and materials relating to cd84-like polypeptides and polynucleotides
EP1308459A3 (en) Full-length cDNA sequences
WO2001038486A3 (en) Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
CA2253238A1 (en) Novel agouti-related gene
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
EP1440981A3 (en) Full-length human cdna
PL299053A1 (en) Amino acid compound being a nucleic acid, vector, host cell, genomic zyme clone, method of diagnozing the alzheimer disease, method of determining and expressing a nucleic acid sequence
WO2001053454A3 (en) Methods and materials relating to g protein-coupled receptor-like polypeptides and polynucleotides
CA2167693A1 (en) Melanoma-inhibiting protein
EP1574520A3 (en) Methods and materials relating to neuronal guidance molecule-like (NGM-like) polypeptides and polynucleotides
WO2003029405A3 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2004031362A3 (en) Multimeric protein engineering
WO2001055335A3 (en) Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
WO2001053456A3 (en) Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
WO2001075064A3 (en) Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
WO2001053500A8 (en) Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides
WO2001055333A8 (en) Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
WO2001055337A3 (en) Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
WO2001057175A3 (en) Methods and materials relating to neurotrimin-like polypeptides and polynucleotides
WO2001055332A3 (en) Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
WO2001057233A3 (en) Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
WO2000004041A3 (en) Methods and molecules relating to cd39-like polypeptides
WO2001055435A3 (en) Methods and materials relating to hematopoietic cytokine-like polypeptides and polynucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2399644

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 557993

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001908832

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001236658

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10311823

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001908832

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001908832

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)